Skip to main content
Caplight Logo









Cargene Therapeutics

Cargene Therapeutics

Private
SingaporeHealthcare & Life Scienceshttps://cargene.com

Last Round

Early Funding

Dec 14, 2021

Total Funding Raised

$19.2M

Company Overview

Cargene Therapeutics is a biotechnology company that develops innovative oligonucleotide therapeutics for liver, cardiometabolic, and ophthalmic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

siRNA therapeuticsoligonucleotide therapeuticsdrug discoverycomputational drug designRNA medicinebiotechgene expression modulationextra-hepatic deliveryliver-targeted deliverypreclinical biopharmain silico drug discoverynucleic acid therapeuticsprecision medicinebiotech licensingundruggable targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cargene Therapeutics Comparables

Compare Cargene Therapeutics with similar companies based on industry and business-model similarity.

Cargene Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sanegene Bio
85%
Rona Therapeutics
83%
Switch Therapeutics
81%

Cargene Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingDec 14, 2021

Cargene Therapeutics Investors

Notable investors and investment history

Cargene Therapeutics investors
InvestorRounds
BioTrack CapitalEarly Funding
Hyfinity InvestmentsEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 13, 2024

    Monthly visitors increased 287% MoM, from 310 to 1.2K.

  • Oct 29, 2024

    Monthly visitors grew 123% MoM, from 139 to 310.

Cargene Therapeutics Filings

Explore SEC and related filing metadata, where available.

Cargene Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cargene Therapeutics's valuation, stock price, and market status.

Is Cargene Therapeutics a public or private company?

Cargene Therapeutics is a private company.

What is the current stock price of Cargene Therapeutics?

Cargene Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Cargene Therapeutics worth (valuation)?

Valuation information for Cargene Therapeutics is not publicly available.

Can I buy Cargene Therapeutics stock?

Cargene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cargene Therapeutics's last funding round?

Cargene Therapeutics's most recent funding round was Pre Seed on December 14, 2021.

Who are the main investors in Cargene Therapeutics?

Key investors in Cargene Therapeutics include BioTrack Capital.

Will Cargene Therapeutics IPO soon?

No public IPO plans have been announced for Cargene Therapeutics.

How can I track Cargene Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cargene Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range3
Year Founded2020
Last FundingDec 14, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?